Stifel Financial’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Stifel Financial’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-267,582	Closed	-$142K	–	3207
2019 Q4	$142K	Sell	267,582 -92	-0%	-$223	﹤0.01%	2845
2019 Q3	$1.02M	Buy	267,674 +8	+0%	+$29	﹤0.01%	1742
2019 Q2	$1.78M	Sell	267,666 -84	-0%	-$320	﹤0.01%	1422
2019 Q1	$950K	Buy	267,750 +153,400	+134%	+$832K	﹤0.01%	1681
2018 Q4	$452K	Buy	114,350 +95	+0.1%	+$1.22K	﹤0.01%	1989
2018 Q3	$2.25M	Sell	114,255 -10	-0%	-$253	0.01%	1195
2018 Q2	$3.63M	Buy	114,265 +83,982	+277%	+$3.02M	0.01%	940
2018 Q1	$1.12M	Buy	+30,283	New	+$1.99M	﹤0.01%	1494

Stifel Financial's MLNT Position: Q1 2020 in Review

Stifel Financial sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 267,582 shares — an estimated $142K sold.

Stifel Financial first reported a position in MLNT in Q1 2018 and held it in 8 quarters. The position peaked at $3.63M in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Stifel Financial reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Stifel Financial sold 267,582 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $142K.
Stifel Financial first reported a position in Melinta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 8 quarters.
Stifel Financial's Melinta Therapeutics, Inc. Common Stock position peaked at $3.63M in Q2 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Stifel Financial's 13F filing for Q1 2020, filed 14 May 2020.